Clinical trials: Anticoagulant Drugs
Anticoagulants and Bleeding Disorders, Tissue Adhesion
Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices
This study aimed to clarify the safety of anticoagulant therapy after glue injection for cirrhotic variceal bleeding patients with portal vein thrombosis.
- Conditions
- Anticoagulants and Bleeding Disorders, Tissue Adhesion, Gastric Varices Bleeding
- Trial name
- NCT05545475
- Testing
- Low molecular weight heparin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Hospital of Shandong University
Significant Bleeding Risk
Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
To demonstrate that the efficacy of OCTAPLEX as a reversal agent in patients under Vitamin K Antagonist (VKA) therapy with the need for urgent surgery with significant bleeding risk is clinically non-inferior to that Beriplex®…
- Trial name
- NCT02740335
- Testing
- Octaplex, Beriplex P/N (Kcentra)
- Where
- 86 sites in United States, Belarus and 9 more
- Volunteers
- 208 people
- Sponsor
- Octapharma
Atrial Fibrillation, Medication Adherence
Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence
This is an interventional study designed to develop patient focused strategies that improve adherence to anticoagulant medication in patients with non-valvular atrial fibrillation (AF).
- Trial name
- NCT02690649
- Testing
- Health Messaging (Non-Procedural)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Tammy Toscos
Sarcoma, Soft Tissue Sarcoma
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases
- Trial name
- NCT03244020
- Testing
- Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Where
- 10 sites in United States
- Volunteers
- 2,868 people
- Sponsor
- Massachusetts General Hospital
Anticoagulant Reversal
Clinical Trial Assessing Non-Inferiority of Freeze Dried Plasma to Fresh Frozen Plasma in Reversing Warfarin
The purpose of this research study is to see how well an experimental freeze dried plasma product, known as FDP, works to reverse the anticoagulation effects of a prescription medication called warfarin sodium (warfarin) compared…
- Trial name
- NCT04794348
- Testing
- Fresh Frozen Plasma (FFP), Freeze Dried Plasma (FDP)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Teleflex
Atrial Fibrillation (AF)
A Pharmacist-Led Education Program to Improve Adherence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation
Atrial fibrillation (irregular heartbeat) increases the risk of stroke, and patients are commonly treated with direct oral anticoagulants (DOACs).
- Trial name
- PharmAD-AF (NCT07159399)
- Testing
- Pharmacist-led patient education, Usual Care
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- National Taiwan University
Stroke, Ischemic
Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial
The overall aim of this research is to improve secondary stroke prevention for older patients with stroke. In current practice, patients with stroke are often prescribed antiplatelet therapy with either aspirin or clopidogrel to…
- Trial name
- STROKE75+ (NCT07454707)
- Testing
- Edoxaban 15 mg, Aspirin or clopidogrel
- Where
- Canada
- Volunteers
- 1,204 people
- Sponsor
- Sunnybrook Health Sciences Centre
Atrial Fibrillation
COhort of antithrOmbotic Use and cLinical Outcomes in Patients With Atrial Fibrillation (COOL-AF) Phase 2
Atrial fibrillation (AF) is a leading cause of cardiovascular mortality and morbidity. Asian patients with AF have a higher rate of major bleeding including intracranial hemorrhage (ICH) compared to non-Asians.
- Trial name
- NCT06396299
- Testing
- No intervention
- Where
- 33 sites in Thailand
- Volunteers
- 4,000 people
- Sponsor
- Mahidol University
Healthy
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants
The purpose of the study was to understand the effect of PF-07081532 on the movement of Dabigatran and Rosuvastatin into, though, and out of the body in healthy overweight or obese adult participants.
- Trial name
- NCT05788328
- Testing
- Dabigatran etexilate (DE), Rosuvastatin, PF-07081532
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Anticoagulant-induced Bleeding, Warfarin Sodium Causing Adverse Effects in Therapeutic Use
AI-based Social Software to Manage wARfarin Therapy
The investigators have demonstrated that social software could improve warfarin therapy quality by Human management. however,the efficiency of management will decline if patients' number expands huge.
- Trial name
- AI-SMART (NCT03870581)
- Testing
- AI-based social software management model, Human-based social software management model
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Wuhan Asia Heart Hospital
Hemophilia A, Hemophilia B
Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia
Hemophilia is a rare X-linked bleeding disorder responsible for deficiency of coagulation factor VIII (FVIII) or IX (FIX). The main clinical manifestation is increased bleeding throughout the life which is directly correlated to…
- Conditions
- Hemophilia A, Hemophilia B, Anticoagulant-induced Bleeding
- Trial name
- KADOAH (NCT05804734)
- Testing
- Vitamin K Antagonist - Drug
- Where
- 6 sites in France
- Volunteers
- 54 people
- Sponsor
- Groupe Maladies hémorragiques de Bretagne
Acute Coronary Syndrome
Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes
The purpose of this study is to evaluate the safety and efficacy of various doses of YM150 (the experimental drug) in the prevention of ischemic vascular events in subjects with recent acute coronary syndromes.
- Trial name
- RUBY-1 (NCT00994292)
- Testing
- YM150
- Where
- 131 sites in Argentina, Australia and 19 more
- Volunteers
- 1,276 people
- Sponsor
- Astellas Pharma Europe B.V.
Post-thrombotic Syndrome, Deep Vein Thrombosis Leg
Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis
The goal of this study is to determine the safety and tolerability or efficacy of adjunctive treatments (including rosuvastatin 20 mg daily) in combination with standard anticoagulation therapy (Factor Xa inhibitors) in patients…
- Trial name
- NCT04833764
- Testing
- Rosuvastatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Khanh Nguyen
Anticoagulants, Platelet Aggregation Inhibitors
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
The study will assess the hypothesis that the combination warfarin \& clopidogrel 75 mg/day is superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect to bleeding complications while equally…
- Conditions
- Anticoagulants, Platelet Aggregation Inhibitors, Stents, Atrial Fibrillation
- Trial name
- WOEST (NCT00769938)
- Testing
- PCI (percutaneous coronary intervention)
- Where
- 15 sites in Belgium, Netherlands
- Volunteers
- 573 people, healthy volunteers welcome
- Sponsor
- R&D Cardiologie
Hemorrhage
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
- Trial name
- NCT02104947
- Testing
- idarucizumab
- Where
- 176 sites in United States, Argentina and 31 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
CoMbination of Data From European Cohorts as Part of the European MORPHEUS Project [HORIZON-HLTH-2022-11-01] - "MC-MORPHEUS".
Combine clinical, biological and morphological data from 14 French and European cohorts into a single database.
- Trial name
- MC-MORPHEUS (NCT07328152)
- Where
- France
- Volunteers
- 20,000 people
- Sponsor
- University Hospital, Brest
Atrial Fibrillation
A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF)
The purpose of this observational study is to identify participants with both minor and major bleeds as a result of anticoagulant treatment for AF and evaluating their QoL through both primary and secondary care settings.
- Trial name
- EQUAL-AF (NCT05044533)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
- Trial name
- NCT03551743
- Testing
- PRT064445/Edoxaban
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Recurrent Pregnancy Loss
The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss
In this clinical cohort study, the investigators are going to observe the efficacy of anti-coagulation and immune therapy in the treatment of recurrent pregnancy loss with a prospective randomized controlled trial.
- Trial name
- NCT02990403
- Testing
- Aspirin, Heparin, Prednisone
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai First Maternity and Infant Hospital
Anticoagulant-induced Bleeding, Intracranial Hemorrhages
Anticoagulant-associated Intracranial Hemorrhage
Oral anticoagulant therapy, including factors Xa and 2a inhibitors has become more popular in recent years due to its efficacy and convenience in preventing thrombotic events and reducing the risk for stroke in patients with rosk…
- Trial name
- AAIHINNN (NCT06168838)
- Testing
- Anticoagulant
- Where
- Mexico
- Volunteers
- 1,200 people
- Sponsor
- El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez